Search

Displaying results 4291 - 4300 of 10000 in total
  1. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. … It is being developed by Exelixis, Inc.

  2. Drug

    Lutetium Lu177 Edotreotide

    go.drugbank.com/drugs/DB17278
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Citrulline

    go.drugbank.com/drugs/DB00155
    InvestigationalNutraceutical

    Citrulline is an amino acid. It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. … It is also produced from arginine as a by-product of the reaction catalyzed by NOS family. Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.

    Synonyms: N(delta)-Carbamylornithine, N(5)-(Aminocarbonyl)-L-ornithine
  4. Drug

    Crotalus scutulatus antivenin

    go.drugbank.com/drugs/DB13891
    Approved

    Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom. … Specimens with type A venom, which cause a different pattern of injury than other rattlesnakes, have been reported in southern California, Nevada, Utah, Arizona, Texas, and New Mexico [L2856].

  5. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  6. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  7. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

  8. Drug

    Pemirolast

    go.drugbank.com/drugs/DB00885
    ApprovedWithdrawn

    Pemirolast potassium is a slightly yellow powder that is soluble in water. It is a mast cell stabilizer that acts as an antiallergic agent. … As an ophthalmic aqueous sterile solution, pemirolast is used for the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis.

  9. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.

  10. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes. … ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).